Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Triple Negative Breast Neoplasms

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

ZAS Augustinus, Antwerp, Belgium
Contact: Study coordinator (Kevin Punie, MD) · kevin.punie@gza.be · +3234433737
Contact: Principal Investigator (Kevin Punie, MD)
Antwerp University Hospital, Antwerp, Belgium
Contact: Study coordinator (Sevilay Altintas, MD, PhD) · sevilay.altintas@uza.be · +3238213250
Contact: Principal Investigator (Sevilay Altintas, MD, PhD)
University Hospital Brussels, Brussels, Belgium
Contact: Study coordinator (Christel Fontaine, MD) · christel.fontaine@uzbrussel.be · +3224776040
Contact: Principal Investigator (Christel Fontaine, MD)
Ghent University Hospital, Ghent, Belgium
Contact: Study coordinator (Hannelore Denys, MD, PhD) · hannelore.denys@uzgent.be · +3293322692
Contact: Principal Investigator (Hannelore Denys, MD, PhD)
Jessa Ziekenhuis, Hasselt, Belgium
Contact: Study coordinator (Annelies Requilé, MD) · annelies.requile@jessazh.be · +3211337979
Contact: Principal Investigator (Annelies Requilé, MD)
University Hospitals Leuven, Leuven, Belgium
Contact: Study coordinator (Patrick Neven, MD, PhD) · patrick.neven@uzleuven.be · +3216344750
Contact: Study coordinator (Kristien Borremans, MD) · kristien.borremans@kuleuven.be · +3216347795
Contact: Principal Investigator (Patrick Neven, MD, PhD)

Study leads

Patrick Neven, MD, PhD
Principal Investigator
Universitaire Ziekenhuizen KU Leuven

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

Breast Neoplasm · Triple Negative Breast Cancer (TNBC) · HRD

Abroad (travel likely)RecruitingPHASE2

Bournemouth, United Kingdom · London, United Kingdom

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of the Head and Neck · Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE1

Birmingham, United States · Birmingham, United States

Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy

Breast Neoplasms

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China